Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CrF-ADSC-exo refers to exosomes derived from adipose-derived stem cells (ADSCs) isolated from creeping fat (CrF), a characteristic pathological feature of Crohn's disease. These exosomes are enriched with miR-132-3p, which targets the RASA1/ERK1/2 signaling pathway in lymphatic endothelial cells. By modulating this axis, CrF-ADSC-exo promotes lymphangiogenesis and improves lymphatic drainage, thereby alleviating inflammation in experimental models of colitis and mesenteritis. This research, primarily conducted at Shanghai Tenth People's Hospital, suggests a potential therapeutic role for these exosomes in treating the mesenteric and intestinal complications of Crohn's disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CrF-ADSC-exo.